Thursday 16 October, 2025
Introduction and Objectives Congenital adrenal hyperplasia patients exhibit cortisol deficiency and often require lifelong cortisol replacement therapy. To optimise this…
Read morePoster: Drug/Disease Modelling - Endocrine
Pharmacokinetic Modeling of Enavogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Korean Healthy Volunteers and Patients with Type 2 Diabetes Mellitus
Thursday 16 October, 2025
Objectives: Enavogliflozin is a novel sodium-glucose cotransporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This…
Read moreLongitudinal Biomarker Modeling of T2D-Patients Treated With Semaglutide
Thursday 16 October, 2025
Introduction: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a significant advancement in the treatment of type 2…
Read moreComparison of immediate- and modified-release hydrocortisone to achieve therapeutic goals in congenital adrenal hyperplasia
Thursday 16 October, 2025
Introduction and objectives: Congenital adrenal hyperplasia (CAH) is a rare genetic disease characterised by reduced cortisol production. Cortisol production is…
Read moreA Population-based Time-to-Event Model for Pregnancy Loss Risk Prediction in frozen-thawed embryo transfer (FET)
Thursday 16 October, 2025
BACKGROUND: Pregnancy loss (PL) after FET imposes significant physiological and mental burden on the patients, and reduced success rates of…
Read more